LBL Biotech Inc.
October 17, 2023
Franciscan C
Oncology
LBL Biotec. Inc. is a spin-off company from National Cheng-kung University at Taiwan. The company focusses on the development of IL-20 antibody to treat several inflammation-associated diseases such as pancreatic cancer ( PDAC), hepatoma, breast cancer etc. The drug is currently in the phase 1/2A human clinical trial on patients with solid tumors.
Speakers
Company Type
Privately Funded
Country
Taiwan
Website
http://The website of the company is under construction and will be completed by the end of August.
CEO/Top Company Official
Mingshi Chang, Ph.D
Lead Product in Development
Using IL-20 monoclonal antibody to treat PDAC, hepatoma, breast cancer, liver cirrhosis etc. It is currently in human Phase 1/2A clinical trial.
Number Of Unlicensed Products
More than 40 patents using IL-20 antibody to treat several indications such as oncology, liver cirrhosis , chemo-induced neuropathy
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)